Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Syndax Pharmaceuticals Inc | sndx-ex321_11.htm |
| EX-31.2 - EX-31.2 - Syndax Pharmaceuticals Inc | sndx-ex312_10.htm |
| EX-31.1 - EX-31.1 - Syndax Pharmaceuticals Inc | sndx-ex311_8.htm |
| EX-10.47 - EX-10.47 - Syndax Pharmaceuticals Inc | sndx-ex1047_509.htm |
| EX-10.34 - EX-10.34 - Syndax Pharmaceuticals Inc | sndx-ex1034_508.htm |
| 10-K - 10-K - Syndax Pharmaceuticals Inc | sndx-10k_20171231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-210412 and 333-220172 on Form S-8 and Registration Statement No. 333-217172 on Form S-3 of our report dated March 8, 2018, relating to the financial statements of Syndax Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 8, 2018